Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine

A Randomized, Parallel, 3-arm Study to Characterize the Effect of Ipilimumab + Chemotherapy in Patients With Untreated Advanced Melanoma

The purpose of this clinical research study is to learn the pharmacokinetics of Ipilimumab when combined with Paclitaxel/Carboplatin or Dacarbazine

Inclusion Criteria:

• Histologic diagnosis of advanced malignant melanoma
• Eastern Cooperative Oncology Group (ECOG) performances status 0-1
• Measurable/evaluable disease as per modified World Health Organization (mWHO) criteria

Exclusion Criteria:

• Evidence of active brain metastases
• Prior treatment with anti-cytotoxic lymphocyte antigen 4 (CTLA-4) or anti-CD137 (type of tumor necrosis factor) antibody
• Total Bilirubin greater than (>) 1.5 * upper limit of normal (ULN) and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 * upper limit of normal (ULN)
• Prior Autoimmune disease
• Use of immunosuppressing therapies